Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
PLETHICO PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PLETHICO PHARMA Mar-14 |
ADCOCK INGRAM Jun-14 |
PLETHICO PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 254 | 315 | - | |
Low | Rs | 31 | 228 | - | |
Sales per share (Unadj.) | Rs | 604.6 | 93.8 | - | |
Earnings per share (Unadj.) | Rs | 32.5 | -23.6 | - | |
Cash flow per share (Unadj.) | Rs | 51.3 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 473.7 | 73.6 | - | |
Shares outstanding (eoy) | m | 34.07 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.2 | 2.9 | 8.2% | |
Avg P/E ratio | x | 4.4 | -11.5 | -38.2% | |
P/CF ratio (eoy) | x | 2.8 | -13.9 | -20.0% | |
Price / Book Value ratio | x | 0.3 | 3.7 | 8.2% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 4,859 | 45,814 | 10.6% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 1,547 | 2,875 | 53.8% | |
Avg. sales/employee | Rs Th | 0 | 3,688.3 | - | |
Avg. wages/employee | Rs Th | 0 | 669.8 | - | |
Avg. net profit/employee | Rs Th | 0 | -929.4 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 20,598 | 15,834 | 130.1% | |
Other income | Rs m | 419 | 111 | 378.3% | |
Total revenues | Rs m | 21,017 | 15,945 | 131.8% | |
Gross profit | Rs m | 2,938 | -2,744 | -107.1% | |
Depreciation | Rs m | 642 | 683 | 94.0% | |
Interest | Rs m | 1,747 | 429 | 407.2% | |
Profit before tax | Rs m | 968 | -3,745 | -25.9% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -138 | 234 | -59.1% | |
Profit after tax | Rs m | 1,107 | -3,990 | -27.7% | |
Gross profit margin | % | 14.3 | -17.3 | -82.3% | |
Effective tax rate | % | -14.3 | -6.2 | 228.7% | |
Net profit margin | % | 5.4 | -25.2 | -21.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 18,877 | 11,597 | 162.8% | |
Current liabilities | Rs m | 11,896 | 6,525 | 182.3% | |
Net working cap to sales | % | 33.9 | 32.0 | 105.8% | |
Current ratio | x | 1.6 | 1.8 | 89.3% | |
Inventory Days | Days | 78 | 111 | 70.4% | |
Debtors Days | Days | 198 | 124 | 159.6% | |
Net fixed assets | Rs m | 14,269 | 6,760 | 211.1% | |
Share capital | Rs m | 341 | 74 | 463.4% | |
Net worth | Rs m | 16,139 | 12,428 | 129.9% | |
Long term debt | Rs m | 4,706 | 4,367 | 107.7% | |
Total assets | Rs m | 33,146 | 23,477 | 141.2% | |
Interest coverage | x | 1.6 | -7.7 | -20.1% | |
Debt to equity ratio | x | 0.3 | 0.4 | 83.0% | |
Sales to assets ratio | x | 0.6 | 0.7 | 92.1% | |
Return on assets | % | 8.6 | -15.2 | -56.8% | |
Return on equity | % | 6.9 | -32.1 | -21.4% | |
Return on capital | % | 13.0 | -19.8 | -65.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,437 | 1,352 | 180.3% | |
From Investments | Rs m | -6,265 | -415 | 1,509.6% | |
From Financial Activity | Rs m | 2,490 | 3,964 | 62.8% | |
Net Cashflow | Rs m | 24 | 4,900 | 0.5% |
Compare PLETHICO PHARMA With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare PLETHICO PHARMA With: FREDUN PHARMA BH.IMMUN&BIO WOCKHARDT CONCORD DRUGS JENBURKT PH.
Japan's Nikkei 225 led gains in Asia as markets in the region rose across the board, following Wall Street's continued rally for a second straight day.